Although the current model cannot resemble the microenvironment of bone metastatic prostate cancer, these results as a proof-of-principle study demonstrate the efficacy of Ad-522E-TK plus GCV gene therapy for the treatment of CRPC prostate cancer. Here, TKT is linked to prostate carcinoma.